Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide

Biochemical Pharmacology

Volumn 72, Issue 6, 2006, Pages 719-728

  Irwin, Nigel ^a   Clarke, Gillian C ^a   Green, Brian D ^a   Greer, Brett ^b   Harriott, Patrick ^b   Gault, Victor A ^a   O'Harte, Finbarr P M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Analogues; Glucose homeostasis; Glucose dependent insulinotropic polypeptide; ob ob mice; Type 2 diabetes

Indexed keywords

ACETIC ACID DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCOSE; INSULIN; PALMITIC ACID DERIVATIVE; SODIUM CHLORIDE;

ACYLATION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CIRCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EVIDENCE BASED MEDICINE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN METABOLISM; INSULIN RELEASE; INSULIN SENSITIVITY; MORPHOLOGY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; OBESITY; PANCREAS; PANCREAS ISLET; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TREATMENT DURATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; INSULIN; MICE; MICE, OBESE; PANCREAS;

EID: 33747188115     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.06.013     Document Type: Article

References (38)

1. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63 (1986) 492-498
2. Nauck M.A., Bartels E., Orskov C., Ebert R., and Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76 (1993) 912-917
3. Wang Y., Montrose-Rafizadeh C., Adams L., Raygada M., Nadiv O., and Egan J.M. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN cells 1046-38. Mol Cell Endocrinol 116 (1996) 81-87
4. Trumper A., Trumper K., Trusheim H., Arnold R., Goke B., and Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15 (2001) 1559-1570
5. Ehses J.A., Casilla V.R., Doty T., Pospisilik J.A., Winter K.D., Demuth H.U., et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144 (2003) 4433-4445
6. Rudovich N.N., Rochlitz H.J., and Pfeiffer A.F. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 53 (2004) 2359-2365
7. O'Harte F.P.M., Gray A.M., and Flatt P.R. Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J Endocrinol 156 (1998) 237-243
8. Gault V.A., Flatt P.R., and O'Harte F.P.M. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 308 (2003) 207-213
9. Pederson R.A., and Brown J.C. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99 (1976) 780-785
10. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
11. Gault V.A., Parker J.C., Harriott P., Flatt P.R., and O'Harte F.P.M. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide (GIP), GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 175 (2002) 525-533
12. Meier J.J., Nauck M.A., Kranz D., Holst J.J., Deacon C.F., Gaeckler D., et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53 (2004) 654-662
13. Irwin N., Green B.D., Gault V.A., Greer B., Harriott P., Bailey C.J., et al. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivatized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. J Med Chem 48 (2005) 1244-1250
14. 2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes 48 (1999) 758-765
15. 2]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51 (2002) 656-661
16. Gault V.A., O'Harte F.P.M., and Flatt P.R. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?. Neuropeptides 37 (2003) 253-263
17. Irwin N., Green B.D., Mooney M.H., Greer B., Harriott P., Bailey C.J., et al. A novel, long-acting agonist of glucose dependent insulinotropic polypeptide (GIP) suitable for once daily administration in type 2 diabetes. J Pharm Exp Therap 314 (2005) 1187-1194
18. O'Harte F.P.M., Gault V.A., Parker J.C., Harriott P., Mooney M.H., Bailey C.J., et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45 (2002) 1281-1291
19. 37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J Med Chem 49 (2006) 1047-1054
20. Kim S.J., Winter K., Nian C., Tsuneoka M., Koda Y., and McIntosh C.H.S. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 and downregulation of bax expression. J Biol Chem 280 (2005) 22297-22307
21. 8-substituted GLP-1 analogues. Biol Chem 385 (2004) 169-177
22. Kurtzhals P., Havelund S., Jonassen I., Kiehr B., Larsen U.D., Ribel U., et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312 (1995) 725-731
23. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43 (2000) 1664-1669
24. Bailey C.J., and Flatt P.R. Influence of genetic background and age on the expression of the obese hyperglycemic syndrome in Aston ob/ob mice. Int J Obesity 6 (1982) 11-21
25. 37PAL). Biol Chem 386 (2005) 379-387
26. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-diabetes. Diabetes 54 (2005) 2436-2446
27. Meier J.J., Nauck M.A., Schmidt W.E., and Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 107 (2002) 1-13
28. Meier J.J., Nauck M.A., Siepmann N., Greulich M., Holst J.J., Deacon C.F., et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 52 (2003) 1579-1585
29. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 (1993) 301-307
30. Kjems L.L., Holst J.J., Volund A., and Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52 (2003) 380-386
31. O'Harte F.P.M., Mooney M.H., and Kelly C.M.N. Flatt PR Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J Endocrinol 165 (2002) 639-648
32. Meier J.J., Goetze O., Anstipp J., Hagemann D., Holst J.J., Schmidt W.E., et al. Gastric inhibitory polypeptide (GIP) does not inhibit gastric emptying in man. Am J Phys Endocrinol Metab 286 (2003) E621-E625
33. Meier J.J., Gallwitz B., Siepmann N., Holst J.J., Deacon C.F., Schmidt W.E., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46 (2003) 798-801
34. Trumper A., Trumper K., and Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 174 (2002) 233-246
35. Meier J.J., Gallwitz B., Kask B., Deacon C.F., Holst J.J., Schmidt W.E., et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 53 S3 (2004) 220-224
36. Oben J., Morgan L.M., Fletcher J., and Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 130 (1991) 267-272
37. Delmeire D., Flamez D., Moens K., Hinke S.A., Van Schravendiik C., Pipeleers D., et al. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. Biochem Pharmacol 68 (2004) 33-39
38. Baggio L.L., and Drucker D.J. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 57 (2006) 265-281